secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001493152-26-013088
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA presents THIO-101 data at ELCC showing sustained response in relapsed NSCLC
--------------------------------------------------------------------------------

- Poster presented at European Lung Cancer Congress 2026 in Copenhagen on March 27, 2026.
- Data from THIO-101 trial: Ateganosine + ICI in relapsed NSCLC patients.
- Poster title indicates sustained response and long-term therapeutic benefits after treatment cessation.
- No financial or numerical efficacy data disclosed in the 8-K; poster available on company website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226013088/0001493152-26-013088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226013088/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer